Retlirafusp alfa

瑞拉芙普-α

Report date: 2026/04/24 20:01:59

Base Information

Drug NameRetlirafusp alfa
Drug Alias Name瑞拉芙普α艾泽利SHR-1701
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionProgrammed death-ligand 1 blockersTransforming growth factor beta inhibitors
TargetsProgrammed death-ligand 1Transforming growth factor beta
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursProstatic Neoplasms, Castration-Resistant +[21] 
Global Approved IndicationsStomach NeoplasmsEsophageal Neoplasms
Approved Indications in ChinaStomach NeoplasmsEsophageal Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2026/01/07
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesPla General HospitalShanghai Zhongshan HospitalFudan University +[9] 
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursProstatic Neoplasms, Castration-Resistant +[17] 
Inactive IndicationsUterine Cervical NeoplasmsLung NeoplasmsRectal Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A